ClinicalTrials.gg
CompletedNCT07688902Updated Nov 12, 2026

Comparing 5% Dextrose Injections Into or Around Partial Supraspinatus Tendon Tears

An interventional study of Intralesional 5% Dextrose Injection and Perilesional 5% Dextrose Injection in Partial Supraspinatus Tendon Tear, sponsored by Ankara City Hospital Bilkent. Completed at 1 site in Turkey (Türkiye). Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-11-12.

Sponsored by Ankara City Hospital Bilkent · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 1 year 4 months after the study started (first participant enrolled Feb 2025, registered Jun 2026).
Updated Nov 12, 2026Now CompletedPrimary completion moved+5 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
46
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 167 studies in Shoulder Pain with a site in Turkey — 41 open to participants now, 44 under way, none of them phase 3. Shoulder Pain · Turkey.

Enrollment
71st of 126
46 · median 50
Started
2025
with 23 others
No phase
124 of 167
33 open now
Registered
156th of 167
by date
Lead sponsor
6 of 167
Ankara City Hospital Bilkent

Among the 167 studies in Shoulder Pain with a site in Turkey, this one is the 71st largest by enrollment of the 126 interventional ones that give a count, is one of 24 that started in 2025, is one of 124 with no phase, and was the 156th registered.

Shoulder Pain

738 studies on the registry are indexed under Shoulder Pain; 168 are open to participants now.

Browse Shoulder Pain studies →

Open to participants now

41 of the 167 studies in Shoulder Pain with a site in Turkey are open now. Recruiting first, the newest first:

36 more — sign in →

All 41 open studies →

A study can be open while its sites in Turkey have not opened yet or have stopped. Only those recruiting at a site in Turkey →

Who these studies take

Of the 90 Shoulder Pain studies recruiting now, 25 (28%) set no upper age limit and 55 (61%) stop at 75 or younger; 3 take children under 18; 15 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 167 studies in Shoulder Pain with a site in Turkey, or all of them as a file.
02

Study summary

This prospective, single-center randomized trial compared ultrasound-guided intralesional and perilesional 5% dextrose injections in adults with partial supraspinatus tendon tears. Participants and outcome assessors were blinded to group assignment. Forty-six participants were randomized equally to the two groups, and 40 completed follow-up and were included in the final analysis (20 per group).

Both groups received ultrasound-guided injections at baseline and at study weeks 3 and 6. At each session, both groups received a 5% dextrose injection at the supraspinatus tendon attachment. An additional injection was given either directly into the tear or into the tendon tissue around it, depending on group assignment. Both groups began the same home exercise program after the first injection.

Shoulder pain, disability, and health-related quality of life were assessed at baseline and at study weeks 9 and 12. Tear dimensions and supraspinatus tendon thickness were measured by ultrasonography at baseline and at study week 12.

Read the detailed description

This prospective, single-center, parallel-group randomized trial enrolled adults aged 18 to 75 years with symptomatic partial supraspinatus tendon tears. An independent researcher generated the 1:1 allocation sequence using a computer-based random number generator. Allocation was concealed in sequentially numbered, opaque, sealed envelopes. The injecting physician opened the envelopes after the baseline clinical and ultrasonographic assessments. Participants and outcome assessors were blinded to group assignment.

Both groups received three ultrasound-guided 5% dextrose injection sessions at baseline and at study weeks 3 and 6. At each session, 2 mL was distributed across three points at the supraspinatus tendon enthesis in both groups. An additional 2 mL was injected into the tendon defect in the intralesional group or into the tendon tissue surrounding the defect in the perilesional group using a peppering technique. The total injection volume was 4 mL per session in both groups. Participants began the same standardized home exercise program after the first injection and were instructed to perform it twice daily throughout the study.

Clinical outcomes were assessed at baseline and at study weeks 9 and 12. Mean daytime pain, worst daytime pain, and night pain were recorded separately using the Numeric Rating Scale. Shoulder pain and disability were assessed using the Shoulder Pain and Disability Index, and health-related quality of life was assessed using the 12-Item Short Form Health Survey. Short-axis and long-axis defect diameters and supraspinatus tendon thickness were measured by ultrasonography at baseline and at study week 12.

03

Conditions studied

  • Partial Supraspinatus Tendon Tear

Browse trials for

Keywords

  • Dextrose injection
  • Prolotherapy
  • Intralesional injection
  • Perilesional injection
  • Partial rotator cuff tear
  • Supraspinatus tendon
  • Ultrasound-guided injection
  • Shoulder Pain and Disability Index
  • Numeric Rating Scale
  • Ultrasonography
04

Who can participate

The criteria were revised on the registry on Nov 12, 2026. See what changed

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 18 to 75 years
  • Shoulder pain and functional limitation for at least 3 months
  • Partial supraspinatus tendon tear identified on magnetic resonance imaging performed within the previous 6 months and confirmed by ultrasonography at study entry. Articular-sided, bursal-sided, and intrasubstance tears were eligible.
  • At least one positive Neer, Hawkins-Kennedy, or painful arc test
  • Ability to attend follow-up visits
  • Written to participate

For participants with bilateral involvement, only the more painful shoulder was included.

Exclusion criteria

Exclusion Criteria:

  • - Full-thickness supraspinatus tendon tear
  • Major pathology of rotator cuff tendons other than the supraspinatus
  • Advanced acromioclavicular or glenohumeral osteoarthritis
  • Marked adhesive capsulitis
  • Previous shoulder surgery
  • , -rich plasma, or prolotherapy injection into the affected shoulder within the previous 3 months
  • Active infection, including infection at the injection site
  • Skin lesion at the injection site
  • Bleeding diathesis or anticoagulant use
  • Known allergy or intolerance to dextrose
  • Uncontrolled diabetes mellitus ( >8.5%)
  • Severe endocrine or metabolic disease
  • Rheumatologic disease involving the shoulder
  • Neurological disease affecting shoulder function
  • Pregnancy
  • Active
  • Cognitive impairment preventing reliable completion of questionnaires
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
46 participants (actual)

Study arms

  • Experimental
    Intralesional 5% Dextrose Injection

    Participants received three ultrasound-guided 5% dextrose injection sessions at baseline and at study weeks 3 and 6. At each session, dextrose was injected at the supraspinatus tendon enthesis and directly into the partial tendon tear. Participants began the same standardized home exercise program as the perilesional group after the first injection.

    Procedure: Intralesional 5% Dextrose Injection

  • Active comparator
    Perilesional 5% Dextrose Injection

    Participants received three ultrasound-guided 5% dextrose injection sessions at baseline and at study weeks 3 and 6. At each session, dextrose was injected at the supraspinatus tendon enthesis and into the tendon tissue surrounding the margins of the partial tear. Participants began the same standardized home exercise program as the intralesional group after the first injection.

    Procedure: Perilesional 5% Dextrose Injection

Interventions

  • ProcedureIntralesional 5% Dextrose Injection

    At each ultrasound-guided session, 2 mL of 5% dextrose was distributed across three points at the supraspinatus tendon enthesis. An additional 2 mL was injected directly into the partial tendon defect using a peppering technique. The total volume was 4 mL per session.

  • ProcedurePerilesional 5% Dextrose Injection

    At each ultrasound-guided session, 2 mL of 5% dextrose was distributed across three points at the supraspinatus tendon enthesis. An additional 2 mL was injected into the tendon tissue surrounding the margins of the partial tear using a peppering technique. The total volume was 4 mL per session.

06

What researchers measure

Primary outcomes

  1. Change in Shoulder Pain Intensity Assessed by Numeric Rating Scale

    Mean daytime shoulder pain, worst daytime shoulder pain, and night pain were assessed separately using an 11-point Numeric Rating Scale (NRS). Each score ranged from 0 (no pain) to 10 (worst imaginable pain). Higher scores indicated greater pain intensity.

    Time frame: Baseline and study weeks 9 and 12.

Secondary outcomes

  1. Change in Shoulder Pain and Disability Assessed by the Shoulder Pain and Disability Index

    The Shoulder Pain and Disability Index (SPADI) was used to assess shoulder pain and disability. The pain subscale contains 5 items, and the disability subscale contains 8 items. The two subscales were scored separately on a 0-100 scale. Higher scores indicated greater pain or disability.

    Time frame: Baseline and study weeks 9 and 12.

  2. Change in Health-Related Quality of Life Assessed by the Short Form-12 Health Survey

    Health-related quality of life was assessed using the 12-Item Short Form Health Survey (SF-12). The Physical Component Summary (PCS) and Mental Component Summary (MCS) scores were calculated separately. Higher scores indicated better health-related quality of life in the corresponding component.

    Time frame: Baseline and study weeks 9 and 12.

  3. Change in Supraspinatus Tendon Thickness Assessed by Ultrasonography

    Supraspinatus tendon thickness was measured in millimeters using shoulder ultrasonography with a 5-12 MHz linear transducer.

    Time frame: Baseline and study week 12.

  4. Change in Partial Rotator Cuff Defect Size Assessed by Ultrasonography

    The short-axis and long-axis diameters of the partial supraspinatus tendon tear were measured separately in millimeters using electronic calipers on the ultrasound images that best displayed the defect.

    Time frame: Baseline and study week 12.

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No — Individual participant data will not be shared due to privacy and ethical restrictions.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2025 to primary completion in Feb 2026, 12 months.

Of 351 non-industry interventional studies with no phase under Shoulder Pain, half reached primary completion within 11 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 26. This study's 12 months is close to that.

Counting every sponsor, half of 356 studies reached it within 11 months; a quarter within 4 and three quarters within 27.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 12, 2026: primary completion Oct 2026 → Feb 2026 and completion Oct 2026 → Feb 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jun 30, 2026
First posted
Jul 7, 2026
StartActual
Feb 1, 2025
Primary completionActual
Feb 1, 2026was Oct 2026
CompletionActual
Feb 1, 2026was Oct 2026
Last update
Nov 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Completed
changed Nov 12, 2026
Primary completion
Oct 1, 2026→Feb 1, 2026 (actual)
Nov 12, 2026
Study completion
Oct 1, 2026→Feb 1, 2026 (actual)
Nov 12, 2026
Enrollment
30 (estimated)→46 (actual)
Nov 12, 2026
Eligibility
4 inclusion criteria edited, 3 added, 2 removed; 8 exclusion criteria edited, 6 added, 5 removed
What changed in the criteria
Inclusion criteria
  • RemovedDiagnosis of partial rotator cuff tear by a specialist physician after appropriate clinical examination and imaging evaluation
  • EditedAge between 18 andto 75 years
  • EditedShoulder pain and functional limitation lasting for at least 3 months
  • AddedPartial supraspinatus tendon tear identified on magnetic resonance imaging performed within the previous 6 months and confirmed by ultrasonography at study entry. Articular-sided, bursal-sided, and intrasubstance tears were eligible.
  • EditedClinically confirmed shoulder impingement findings, defined as atAt least one positive test among Neer, Hawkins-Kennedy, or painful arc teststest
  • EditedAbility to comply with the study procedures and attend follow-up visits regularly
  • RemovedWillingness to participate in the study and provide written informed consent
  • AddedWritten informed consent to participate
  • AddedFor participants with bilateral involvement, only the more painful shoulder was included.
Exclusion criteria
  • Edited- Full-thickness rotator cuffsupraspinatus tendon tear
  • RemovedMajor tendon pathology other than the supraspinatus tendon, such as full-thickness subscapularis tear or biceps tendon rupture
  • RemovedAdvanced acromioclavicular joint osteoarthritis, marked impingement, or marked adhesive capsulitis
  • RemovedAdvanced glenohumeral joint arthritis
  • AddedMajor pathology of rotator cuff tendons other than the supraspinatus
  • AddedAdvanced acromioclavicular or glenohumeral osteoarthritis
  • AddedMarked adhesive capsulitis
  • EditedIntra-articular shoulder injection, including steroidCorticosteroid, platelet-rich plasma, or prolotherapy, injection into the affected shoulder within the lastprevious 3 months
  • EditedActive infection, cellulitis, or dermatologic lesionincluding infection at the injection site
  • AddedSkin lesion at the injection site
  • EditedKnown allergy or intolerance to dextrose injection
  • EditedUncontrolled diabetes mellitus, defined as (HbA1c >8.5%, or severe endocrine or metabolic disorder)
  • RemovedImmunosuppression or active infection
  • AddedSevere endocrine or metabolic disease
  • AddedImmunosuppression
  • EditedRheumatologic disease involving the shoulder involvement
  • EditedNeurological disease affecting shoulder movementsfunction
  • EditedAdvanced cognitiveCognitive impairment or dementia preventing reliable completion of questionnaires
  • RemovedRefusal to participate in the study or inability to provide informed consent
Nov 12, 2026
Primary outcomes
1 time frame changed, 1 description edited
What changed in the outcomes
  • Time frameChange in Shoulder Pain Intensity Assessed by Numeric Rating ScaleBaseline, 9 weeks, and 12 weeks after treatment → Baseline and study weeks 9 and 12.
  • DescriptionChange in Shoulder Pain Intensity Assessed by Numeric Rating Scale: how it is measured was reworded
Nov 12, 2026
Secondary outcomes
4 time frame changed, 4 description edited
What changed in the outcomes
  • Time frameChange in Shoulder Pain and Disability Assessed by the Shoulder Pain and Disability IndexBaseline, 9 weeks, and 12 weeks after treatment → Baseline and study weeks 9 and 12.
  • Time frameChange in Health-Related Quality of Life Assessed by the Short Form-12 Health SurveyBaseline, 9 weeks, and 12 weeks after treatment → Baseline and study weeks 9 and 12.
  • Time frameChange in Supraspinatus Tendon Thickness Assessed by UltrasonographyBaseline and 12 weeks after treatment → Baseline and study week 12.
  • Time frameChange in Partial Rotator Cuff Defect Size Assessed by UltrasonographyBaseline and 12 weeks after treatment → Baseline and study week 12.
  • DescriptionChange in Health-Related Quality of Life Assessed by the Short Form-12 Health Survey: how it is measured was reworded
  • DescriptionChange in Partial Rotator Cuff Defect Size Assessed by Ultrasonography: how it is measured was reworded
  • DescriptionChange in Shoulder Pain and Disability Assessed by the Shoulder Pain and Disability Index: how it is measured was reworded
  • DescriptionChange in Supraspinatus Tendon Thickness Assessed by Ultrasonography: how it is measured was reworded
Nov 12, 2026
Title
Intralesional Versus Perilesional 5% Dextrose Injection in Partial Rotator Cuff Tears→Comparing 5% Dextrose Injections Into or Around Partial Supraspinatus Tendon Tears
Nov 12, 2026
Show all 1 update
  1. Nov 12, 2026
    Recruiting→Completed
    Primary completion Oct 1, 2026→Feb 1, 2026 (now actual)
    Study completion Oct 1, 2026→Feb 1, 2026 (now actual)
    Enrollment 30 (estimated)→46 (actual)
    Eligibility 4 inclusion criteria edited, 3 added, 2 removed; 8 exclusion criteria edited, 6 added, 5 removed
    What changed in the criteria
    Inclusion criteria
    • RemovedDiagnosis of partial rotator cuff tear by a specialist physician after appropriate clinical examination and imaging evaluation
    • EditedAge between 18 andto 75 years
    • EditedShoulder pain and functional limitation lasting for at least 3 months
    • AddedPartial supraspinatus tendon tear identified on magnetic resonance imaging performed within the previous 6 months and confirmed by ultrasonography at study entry. Articular-sided, bursal-sided, and intrasubstance tears were eligible.
    • EditedClinically confirmed shoulder impingement findings, defined as atAt least one positive test among Neer, Hawkins-Kennedy, or painful arc teststest
    • EditedAbility to comply with the study procedures and attend follow-up visits regularly
    • RemovedWillingness to participate in the study and provide written informed consent
    • AddedWritten informed consent to participate
    • AddedFor participants with bilateral involvement, only the more painful shoulder was included.
    Exclusion criteria
    • Edited- Full-thickness rotator cuffsupraspinatus tendon tear
    • RemovedMajor tendon pathology other than the supraspinatus tendon, such as full-thickness subscapularis tear or biceps tendon rupture
    • RemovedAdvanced acromioclavicular joint osteoarthritis, marked impingement, or marked adhesive capsulitis
    • RemovedAdvanced glenohumeral joint arthritis
    • AddedMajor pathology of rotator cuff tendons other than the supraspinatus
    • AddedAdvanced acromioclavicular or glenohumeral osteoarthritis
    • AddedMarked adhesive capsulitis
    • EditedIntra-articular shoulder injection, including steroidCorticosteroid, platelet-rich plasma, or prolotherapy, injection into the affected shoulder within the lastprevious 3 months
    • EditedActive infection, cellulitis, or dermatologic lesionincluding infection at the injection site
    • AddedSkin lesion at the injection site
    • EditedKnown allergy or intolerance to dextrose injection
    • EditedUncontrolled diabetes mellitus, defined as (HbA1c >8.5%, or severe endocrine or metabolic disorder)
    • RemovedImmunosuppression or active infection
    • AddedSevere endocrine or metabolic disease
    • AddedImmunosuppression
    • EditedRheumatologic disease involving the shoulder involvement
    • EditedNeurological disease affecting shoulder movementsfunction
    • EditedAdvanced cognitiveCognitive impairment or dementia preventing reliable completion of questionnaires
    • RemovedRefusal to participate in the study or inability to provide informed consent
    Primary outcomes 1 time frame changed, 1 description edited
    What changed in the outcomes
    • Time frameChange in Shoulder Pain Intensity Assessed by Numeric Rating ScaleBaseline, 9 weeks, and 12 weeks after treatment → Baseline and study weeks 9 and 12.
    • DescriptionChange in Shoulder Pain Intensity Assessed by Numeric Rating Scale: how it is measured was reworded
    Secondary outcomes 4 time frame changed, 4 description edited
    What changed in the outcomes
    • Time frameChange in Shoulder Pain and Disability Assessed by the Shoulder Pain and Disability IndexBaseline, 9 weeks, and 12 weeks after treatment → Baseline and study weeks 9 and 12.
    • Time frameChange in Health-Related Quality of Life Assessed by the Short Form-12 Health SurveyBaseline, 9 weeks, and 12 weeks after treatment → Baseline and study weeks 9 and 12.
    • Time frameChange in Supraspinatus Tendon Thickness Assessed by UltrasonographyBaseline and 12 weeks after treatment → Baseline and study week 12.
    • Time frameChange in Partial Rotator Cuff Defect Size Assessed by UltrasonographyBaseline and 12 weeks after treatment → Baseline and study week 12.
    • DescriptionChange in Health-Related Quality of Life Assessed by the Short Form-12 Health Survey: how it is measured was reworded
    • DescriptionChange in Partial Rotator Cuff Defect Size Assessed by Ultrasonography: how it is measured was reworded
    • DescriptionChange in Shoulder Pain and Disability Assessed by the Shoulder Pain and Disability Index: how it is measured was reworded
    • DescriptionChange in Supraspinatus Tendon Thickness Assessed by Ultrasonography: how it is measured was reworded
    Title Intralesional Versus Perilesional 5% Dextrose Injection in Partial Rotator Cuff Tears→Comparing 5% Dextrose Injections Into or Around Partial Supraspinatus Tendon Tears
    + 8 other changes: verification date, responsible party, description, conditions, design details, arm descriptions, contact details and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07688902
Responsible party
Esra Ülgen Kıratlıoğlu (Principal Investigator, Ankara City Hospital Bilkent) — Principal investigator
First posted
Jul 7, 2026
Start date
Feb 1, 2025
Primary completion
Feb 1, 2026
Completion
Feb 1, 2026
Last update
Nov 12, 2026

Study contacts

ESRA Ülgen Kıratlıoğlu
principal investigator · Ankara City Hospital Bilkent

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion